NovoThirteen

CagriSema (cagrilintide + semaglutide) is a fixed-dose combination therapy in Phase 3 development by NovoThirteen for the treatment of obesity. The program combines cagrilintide, a novel acylated glucagon-like peptide-1 (GLP-1) receptor agonist, with semaglutide, an established GLP-1 receptor agonist already approved globally for diabetes and obesity indications. The current Phase 3 trial (NCT 2023-509273-24-00) is evaluating subcutaneous doses of 1.0 mg/1.0 mg and 1.7 mg/1.7 mg administered once-weekly in participants with overweight or obesity. Semaglutide itself has achieved regulatory approval across multiple jurisdictions including the United States, European Union, Japan, Australia, and China, with established clinical efficacy in weight management. The combination approach represents a strategy to enhance therapeutic efficacy through dual GLP-1 pathway engagement. Specific efficacy and safety endpoints, trial enrollment status, and expected regulatory timelines have not yet been disclosed. The competitive landscape includes multiple approved obesity and metabolic agents, though GLP-1 receptor agonists have emerged as a dominant therapeutic class. Development status remains active with no publicly disclosed regulatory milestones or approval dates at this time.

Obesity represents a significant unmet medical need with limited pharmacological treatment options demonstrating sustained weight loss efficacy and favorable safety profiles. The global obesity epidemic continues to drive demand for effective therapeutic interventions, with GLP-1 receptor agonists establishing themselves as a cornerstone therapy class. Semaglutide has demonstrated substantial market success in both diabetes and obesity indications, establishing proof-of-concept for this mechanism in weight management. The CagriSema combination strategy addresses a key clinical question: whether dual GLP-1 pathway engagement can achieve superior efficacy compared to monotherapy approaches. This is particularly relevant given the heterogeneity of patient response to existing GLP-1 agonists and the potential for combination therapy to expand the therapeutic window. The commercial significance is substantial, as the obesity pharmacotherapy market has expanded dramatically following GLP-1 agonist approvals. Patients with inadequate response to semaglutide monotherapy or those requiring enhanced efficacy represent a potential target population. The combination approach may also differentiate CagriSema in a competitive landscape increasingly populated by GLP-1-based therapies, positioning it as a next-generation option for patients with overweight or obesity seeking optimized weight management outcomes.

Drug Class: Fixed-dose combination of two GLP-1 receptor agonists.

Modality: Small molecule (as classified in the program data).

Route of Administration: Subcutaneous injection, once-weekly dosing.

Components:

• Cagrilintide: Novel acylated GLP-1 receptor agonist; mechanism of action and specific target details not yet disclosed.
• Semaglutide (OZEMPIC): Established GLP-1 receptor agonist; approved globally for type 2 diabetes and obesity; therapeutic class A10 (Alimentary tract and metabolism).

Mechanism of Action: Specific MOA details for the combination not yet disclosed; however, semaglutide is known to function as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion and promoting satiety.

Related Therapies: Other GLP-1 receptor agonists (liraglutide, tirzepatide); approved obesity agents including SAXENDA (liraglutide).

Patent Status: Not yet disclosed.

Semaglutide (OZEMPIC) Regulatory Status:

• United States: Approved; NDA applications 209637, 213051, 213182, 215256, 218316; ANDA 220314 (generic pathway).
• European Union: Approved; EMA product numbers EMEA/H/C/004174, EMEA/H/C/004953, EMEA/H/C/005422, EMEA/H/C/006426; authorisation dates 26/03/2026, 30/03/2026.
• Japan: Approved; PMDA approval March 2023.
• Australia: Approved; TGA listing with PBS codes 12075M, 12080T, 14149M, 14163K, 14844G, 14846J, 15311W, 15322K; first listed 01/07/2020, with subsequent listings 01/06/2024 and 01/06/2025.
• China: Clinical trials ongoing; NCT05877547 registered.

CagriSema (Fixed-Dose Combination) Regulatory Status: Not yet disclosed. No FDA, EMA, PMDA, or NMPA approval status available. Program remains in Phase 3 clinical development.

Strategic Positioning: NovoThirteen's development of CagriSema represents a combination strategy within the GLP-1 receptor agonist class, leveraging the established efficacy and safety profile of semaglutide while introducing cagrilintide as a novel dual-action component. This approach aligns with industry trends toward combination therapies to optimize therapeutic outcomes in obesity.

Clinical Development Implications: The Phase 3 trial design incorporating two dose levels (1.0 mg/1.0 mg and 1.7 mg/1.7 mg) suggests dose-escalation strategy and potential for flexible dosing. The once-weekly subcutaneous administration maintains convenience parity with semaglutide monotherapy, a key commercial advantage.

Competitive Dynamics: CagriSema enters a market increasingly dominated by GLP-1 receptor agonists, particularly semaglutide itself. Differentiation will depend on demonstrating superior weight loss efficacy, improved tolerability, or enhanced durability compared to semaglutide monotherapy. The fixed-dose combination format may offer convenience benefits but requires clear clinical superiority to justify adoption.

Regulatory Pathway: No regulatory milestones or timelines have been disclosed. Approval timeline, target indication scope (obesity vs. overweight with comorbidities), and regulatory strategy remain unknown.

Future Catalysts: Phase 3 trial completion and topline efficacy/safety data release; regulatory submissions (FDA, EMA, PMDA); potential label expansion discussions; manufacturing and supply chain announcements; partnership or licensing developments.